Literature DB >> 5328470

A comparison of the analgesic effects of methotrimeprazine and morphine in patients with cancer.

W T Beaver, S L Wallenstein, R W Houde, A Rogers.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5328470     DOI: 10.1002/cpt196674436

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  8 in total

Review 1.  Management of insomnia in patients with chronic pain conditions.

Authors:  Frederic Stiefel; Daniele Stagno
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  Identifying patients at risk for, and treatment of major psychiatric complications of cancer.

Authors:  W Breitbart
Journal:  Support Care Cancer       Date:  1995-01       Impact factor: 3.603

3.  Postoperative analgesia--comparison of methotrimeprazine (Nozinan) and meperidine (Demerol) as postoperative analgesia agents.

Authors:  M Minuck
Journal:  Can Anaesth Soc J       Date:  1972-01

4.  [Pain relief in the final stage of cancer.].

Authors:  S Grond; D Zech; G Horrichs-Haermeyer; K A Lehmann
Journal:  Schmerz       Date:  1990-03       Impact factor: 1.107

5.  [Pharmacotherapy of cancer pain. 3. Adjuvant drugs.].

Authors:  N I Cherny; R K Portenoy; M Raber; M Zenz
Journal:  Schmerz       Date:  1995-03       Impact factor: 1.107

6.  Cancer pain assessment and treatment curriculum guidelines. Ad Hoc Committee on Cancer Pain of the American Society of Clinical Oncology.

Authors: 
Journal:  Support Care Cancer       Date:  1993-03       Impact factor: 3.603

7.  O-demethylation of codeine to morphine inhibited by low-dose levomepromazine.

Authors:  M Vevelstad; S Pettersen; C Tallaksen; O Brørs
Journal:  Eur J Clin Pharmacol       Date:  2009-03-24       Impact factor: 2.953

8.  Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review.

Authors:  Isabel Dietz; Andrea Schmitz; Ingrid Lampey; Christian Schulz
Journal:  BMC Palliat Care       Date:  2013-01-19       Impact factor: 3.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.